Isis Pharmaceuticals announces Phase 1 data from elevated lipoprotein study

|By:, SA News Editor

Isis Pharmaceuticals (ISIS) says patients with elevated Lp(a) saw a mean reduction in lipoprotein of 36%, 62%, and 82% for the 100, 200, and 300 mg dose cohorts of ISIS-APO(a)Rx, respectively.

The data is from a Phase 1 dose-escalation study "designed to assess the safety, tolerability and pharmacokinetics" of the antisense drug.

The results support the company's plan to initiate a Phase 2 program in 2014. (PR)